Articles

1. Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report

   • Yoshiharu Suzuki
   • Shingo Ishiguro
   • Mika Suzuki

   Short Communication 26 December 2023

   

2. Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway

   • Liru Huang
   • Fuhong Liu
   • Ping Hu

   Original Article 23 December 2023 Pages: 203 - 213

   

3. Retraction Note: Atrial natriuretic peptide protects against cisplatin‑induced granulocytopenia

   • Takashi Nojiri
   • Hiroshi Hosoda
   • Kenji Kangawa

   Retraction Note 21 December 2023 Pages: 271 - 271

4. Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule

   • Shinji Kobuchi
   • Atsuko Morita
   • Yukako Ito

   Original Article 20 December 2023 Pages: 365 - 379

   

5. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients

   • K. Westerdijk
   • S. D. Krens
   • N. P. van Erp

   Original Article Open access 17 December 2023 Pages: 353 - 364

   

6. Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study

   • Nobuaki Matsubara
   • Shota Kusuhara
   • Toshio Shimizu

   Original Article Open access 13 December 2023 Pages: 341 - 352

   

7. Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer

   • Shengxi Xu
   • Yingfang Shi
   • Sen Li

   Original Article 05 December 2023 Pages: 191 - 202

   

8. Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer

   • Xingyi Lin
   • Ying Tan
   • Yinting Chen

   Original Article 01 December 2023 Pages: 237 - 251

   

9. Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study

   • Carla Biesdorf
   • Xiaowen Guan
   • Akshanth R. Polepally

   Original Article 30 November 2023 Pages: 329 - 339

   

10. Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study

    • Hiroaki Takahashi
    • Yoko Saito
    • Kenzo Kudo

    Original Article 28 November 2023 Pages: 319 - 328

    

11. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

    • Arjun Mittra
    • Geraldine H. O’ Sullivan Coyne
    • Alice P. Chen

    Original Article Open access 27 November 2023 Pages: 177 - 189

    

12. Azithromycin in cancer treatment: envisioning the probable link of mitochondrial dysfunction and necroptosis

    • Siti Nazihahasma Hassan
    • Farizan Ahmad

    Letter to the Editor 14 November 2023

13. Retraction Note: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis

    • Nidhi Nigam
    • Jasmine George
    • Yogeshwer Shukla

    Retraction Note 13 November 2023 Pages: 269 - 269

14. Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults

    • Yizhe Chen
    • David Wyatt
    • Gopal Krishna

    Original Article Open access 13 November 2023 Pages: 307 - 317

    

15. Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?

    • Mourad Hamimed
    • Raynier Devillier
    • Samia Harbi

    Short Communication 13 November 2023

    

16. Acknowledgement of reviewers 2022

    Acknowledgement 08 November 2023 Pages: 511 - 512

17. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms

    • Yuanpei Wang
    • Jing Wen
    • Fang Ren

    Original Article 08 November 2023 Pages: 295 - 306

    

18. A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?

    • Angeline Ginzac
    • Emilie Thivat
    • Xavier Durando

    Original Article Open access 07 November 2023 Pages: 225 - 236

    

19. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?

    • Martina Catalano
    • Andrea Lapucci
    • Giandomenico Roviello

    Review Article Open access 07 November 2023 Pages: 1 - 9

    

20. Effect of vitamin E on doxorubicin and paclitaxel-induced memory impairments in male rats

    • Ahmad A. Altarifi
    • Kareem Sawali
    • Omar Khabour

    Original Article 06 November 2023 Pages: 215 - 224

    

21. Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer

    • Xinyu Wang
    • Shujun Gu
    • Xu Qi

    Original Article 05 November 2023 Pages: 151 - 159

    

22. Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

    • M. Berge
    • J. S. Giraud
    • B. Blanchet

    Letter to the Editor 03 November 2023 Pages: 519 - 521

    

23. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis

    • Yukio Tonozuka
    • Hiroshi Tanaka
    • Yoshihide Kakimoto

    Original Article Open access 03 November 2023 Pages: 137 - 149

    

24. Are novel oral oncolytics underdosed in obese patients?

    • Lishi Lin
    • Ellen K. O. van der Meer
    • Alwin D. R. Huitema

    Original Article Open access 31 October 2023 Pages: 129 - 136

    

25. Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer

    • Yao Liang
    • Osamu Maeda
    • Yuichi Ando

    Original Article 28 October 2023 Pages: 121 - 127

26. Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach

    • Liangang Chen
    • Na Yao
    • Kai Zhang

    Original Article 14 October 2023 Pages: 107 - 119

    

27. Bidirectional pharmacokinetic drug interactions between olaparib and metformin

    • Joanna Stanisławiak-Rudowicz
    • Agnieszka Karbownik
    • Edyta Szałek

    Original Article Open access 10 October 2023 Pages: 79 - 88

    

28. Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer

    • Marie Lambert
    • Mathieu Alonso
    • Etienne Chatelut

    Short Communication 03 October 2023 Pages: 393 - 395

    

29. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    • Sabin Goktas Aydin
    • Yasin Kutlu
    • Ozcan Yildiz

    Original Article 29 September 2023 Pages: 71 - 78

    

30. Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose

    • Bart A. Jessen
    • Paul Cornwell
    • Timothy Hart

    Correction Open access 29 September 2023

    

31. Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy

    • Mohamed J. Saadh
    • Muhammad Ali Abdulllah Almoyad
    • Reza Akhavan-Sigari

    Review Article 28 September 2023 Pages: 439 - 453

    

32. Sodium orthovanadate exhibits anti-angiogenic, antiapoptotic and blood glucose-lowering effect on colon cancer associated with diabetes

    • Kruti Patel
    • Vivek Bora
    • Bhoomika Patel

    Original Article 27 September 2023 Pages: 55 - 70

    

33. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma

    • Hajime Yasuda
    • Naoko Kaga
    • Miki Ando

    Short Communication 26 September 2023 Pages: 265 - 268

    

34. Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells

    • Man-Yuan Li
    • Jiao Zhang
    • Hong Zheng

    Original Article 23 September 2023 Pages: 41 - 54

    

35. Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer

    • Mengfei Cheng
    • Fang Yang
    • Mei Dong

    Original Article 23 September 2023 Pages: 31 - 39

    

36. A phase I study of the ceramide nanoliposome in patients with advanced solid tumors

    • Aaron Ciner
    • Theodore Gourdin
    • Yixing Jiang

    Original Article Open access 22 September 2023 Pages: 23 - 29

    

37. TMEM120A-mediated regulation of chemotherapy sensitivity in colorectal cancer cells

    • Li Wang
    • Xiaoxia Liu

    Original Article 20 September 2023 Pages: 11 - 22

    

38. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes

    • Anna Maria Militello
    • Giulia Orsi
    • Michele Reni

    Original Article 19 September 2023 Pages: 501 - 510

39. The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models

    • Martina Jabloñski
    • María Sol Rodríguez
    • Isabel Alicia Lüthy

    Original Article 19 September 2023 Pages: 485 - 499

    

40. Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

    • Mototsugu Oya
    • Shuichi Kaneko
    • Yutaka Okayama

    Retraction Note Open access 16 September 2023 Pages: 523 - 523

41. Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective

    • Mohamed Ben-Eltriki
    • Gehana Shankar
    • Subrata Deb

    Review Article 15 September 2023 Pages: 419 - 437

    

42. Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients

    • Alireza Abbaspour
    • Mehdi Dehghani
    • Omidreza Firuzi

    Original Article 05 September 2023 Pages: 475 - 483

    

43. A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer

    • Yukitaka Shibata
    • Natsumi Matsumoto
    • Ken-ichi Fujita

    Original Article 31 August 2023 Pages: 465 - 474

    

44. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation

    • Shiyu He
    • Qianhang Shao
    • Qian Jiang

    Original Article 25 August 2023 Pages: 399 - 410

    

45. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection

    • Cléa Tardy
    • Alicja Puszkiel
    • Audrey Thomas Schoemann

    Short Communication 24 August 2023 Pages: 169 - 175

    

46. Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy

    • Junichi Nakagawa
    • Takenori Takahata
    • Takenori Niioka

    Original Article 23 August 2023 Pages: 391 - 398

    

47. Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure

    • Hirotaka Imamaki
    • Mitsuaki Oura
    • Yoshinao Ozaki

    Short Communication Open access 22 August 2023 Pages: 161 - 167

    

48. Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer

    • Kenji Nakahama
    • Motohiro Izumi
    • Tomoya Kawaguchi

    Original Article 22 August 2023 Pages: 381 - 390

    

49. A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype

    • John F. Marcelletti
    • Branimir I. Sikic

    Original Article 21 August 2023 Pages: 369 - 380

    

50. Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations

    • Chukwunonso K. Nwabufo

    Review Article 18 August 2023 Pages: 89 - 105